Brief: Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
21/10/2025 13:31
Oct 21 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS REPORTS FDA ORPHAN DRUG DESIGNATION AND STRONG PRECLINICAL DATA FOR HT-KIT IN RARE C-KIT-DRIVEN CANCERS Source text: ID:nPn4BpwJBa Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology